Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders

There are few studies comparing lesion evolution across different CNS demyelinating diseases, yet knowledge of this may be important for diagnosis and understanding differences in disease pathogenesis. We sought to compare MRI T2 lesion evolution in myelin oligodendrocyte glycoprotein immunoglobulin...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Neurology Ročník 97; číslo 11; s. e1097
Hlavní autori: Sechi, Elia, Krecke, Karl N, Messina, Steven A, Buciuc, Marina, Pittock, Sean J, Chen, John J, Weinshenker, Brian G, Lopez-Chiriboga, A Sebastian, Lucchinetti, Claudia F, Zalewski, Nicholas L, Tillema, Jan Mendelt, Kunchok, Amy, Monaco, Salvatore, Morris, Padraig P, Fryer, James P, Nguyen, Adam, Greenwood, Tammy, Syc-Mazurek, Stephanie B, Keegan, B Mark, Flanagan, Eoin P
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: United States 14.09.2021
Predmet:
ISSN:1526-632X, 1526-632X
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract There are few studies comparing lesion evolution across different CNS demyelinating diseases, yet knowledge of this may be important for diagnosis and understanding differences in disease pathogenesis. We sought to compare MRI T2 lesion evolution in myelin oligodendrocyte glycoprotein immunoglobulin G (IgG)-associated disorder (MOGAD), aquaporin 4 IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG-NMOSD), and multiple sclerosis (MS). In this descriptive study, we retrospectively identified Mayo Clinic patients with MOGAD, AQP4-IgG-NMOSD, or MS and (1) brain or myelitis attack; (2) available attack MRI within 6 weeks; and (3) follow-up MRI beyond 6 months without interval relapses in that region. Two neurologists identified the symptomatic or largest T2 lesion for each patient (index lesion). MRIs were then independently reviewed by 2 neuroradiologists blinded to diagnosis to determine resolution of T2 lesions by consensus. The index T2 lesion area was manually outlined acutely and at follow-up to assess variation in size. We included 156 patients (MOGAD, 38; AQP4-IgG-NMOSD, 51; MS, 67) with 172 attacks (brain, 81; myelitis, 91). The age (median [range]) differed between MOGAD (25 [2-74]), AQP4-IgG-NMOSD (53 [10-78]), and MS (37 [16-61]) ( < 0.01) and female sex predominated in the AQP4-IgG-NMOSD (41/51 [80%]) and MS (51/67 [76%]) groups but not among those with MOGAD (17/38 [45%]). Complete resolution of the index T2 lesion was more frequent in MOGAD (brain, 13/18 [72%]; spine, 22/28 [79%]) than AQP4-IgG-NMOSD (brain, 3/21 [14%]; spine, 0/34 [0%]) and MS (brain, 7/42 [17%]; spine, 0/29 [0%]) ( < 0.001). Resolution of all T2 lesions occurred most often in MOGAD (brain, 7/18 [39%]; spine, 22/28 [79%]) than AQP4-IgG-NMOSD (brain, 2/21 [10%]; spine, 0/34 [0%]) and MS (brain, 2/42 [5%]; spine, 0/29 [0%]) ( < 0.01). There was a larger median (range) reduction in T2 lesion area in mm on follow-up axial brain MRI with MOGAD (213 [55-873]) than AQP4-IgG-NMOSD (104 [0.7-597]) ( = 0.02) and MS (36 [0-506]) ( < 0.001) and the reductions in size on sagittal spine MRI follow-up in MOGAD (262 [0-888]) and AQP4-IgG-NMOSD (309 [0-1885]) were similar ( = 0.4) and greater than in MS (23 [0-152]) ( < 0.001). The MRI T2 lesions in MOGAD resolve completely more often than in AQP4-IgG-NMOSD and MS. This has implications for diagnosis, monitoring disease activity, and clinical trial design, while also providing insight into pathogenesis of CNS demyelinating diseases.
AbstractList There are few studies comparing lesion evolution across different CNS demyelinating diseases, yet knowledge of this may be important for diagnosis and understanding differences in disease pathogenesis. We sought to compare MRI T2 lesion evolution in myelin oligodendrocyte glycoprotein immunoglobulin G (IgG)-associated disorder (MOGAD), aquaporin 4 IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG-NMOSD), and multiple sclerosis (MS). In this descriptive study, we retrospectively identified Mayo Clinic patients with MOGAD, AQP4-IgG-NMOSD, or MS and (1) brain or myelitis attack; (2) available attack MRI within 6 weeks; and (3) follow-up MRI beyond 6 months without interval relapses in that region. Two neurologists identified the symptomatic or largest T2 lesion for each patient (index lesion). MRIs were then independently reviewed by 2 neuroradiologists blinded to diagnosis to determine resolution of T2 lesions by consensus. The index T2 lesion area was manually outlined acutely and at follow-up to assess variation in size. We included 156 patients (MOGAD, 38; AQP4-IgG-NMOSD, 51; MS, 67) with 172 attacks (brain, 81; myelitis, 91). The age (median [range]) differed between MOGAD (25 [2-74]), AQP4-IgG-NMOSD (53 [10-78]), and MS (37 [16-61]) ( < 0.01) and female sex predominated in the AQP4-IgG-NMOSD (41/51 [80%]) and MS (51/67 [76%]) groups but not among those with MOGAD (17/38 [45%]). Complete resolution of the index T2 lesion was more frequent in MOGAD (brain, 13/18 [72%]; spine, 22/28 [79%]) than AQP4-IgG-NMOSD (brain, 3/21 [14%]; spine, 0/34 [0%]) and MS (brain, 7/42 [17%]; spine, 0/29 [0%]) ( < 0.001). Resolution of all T2 lesions occurred most often in MOGAD (brain, 7/18 [39%]; spine, 22/28 [79%]) than AQP4-IgG-NMOSD (brain, 2/21 [10%]; spine, 0/34 [0%]) and MS (brain, 2/42 [5%]; spine, 0/29 [0%]) ( < 0.01). There was a larger median (range) reduction in T2 lesion area in mm on follow-up axial brain MRI with MOGAD (213 [55-873]) than AQP4-IgG-NMOSD (104 [0.7-597]) ( = 0.02) and MS (36 [0-506]) ( < 0.001) and the reductions in size on sagittal spine MRI follow-up in MOGAD (262 [0-888]) and AQP4-IgG-NMOSD (309 [0-1885]) were similar ( = 0.4) and greater than in MS (23 [0-152]) ( < 0.001). The MRI T2 lesions in MOGAD resolve completely more often than in AQP4-IgG-NMOSD and MS. This has implications for diagnosis, monitoring disease activity, and clinical trial design, while also providing insight into pathogenesis of CNS demyelinating diseases.
There are few studies comparing lesion evolution across different CNS demyelinating diseases, yet knowledge of this may be important for diagnosis and understanding differences in disease pathogenesis. We sought to compare MRI T2 lesion evolution in myelin oligodendrocyte glycoprotein immunoglobulin G (IgG)-associated disorder (MOGAD), aquaporin 4 IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG-NMOSD), and multiple sclerosis (MS).BACKGROUND AND OBJECTIVEThere are few studies comparing lesion evolution across different CNS demyelinating diseases, yet knowledge of this may be important for diagnosis and understanding differences in disease pathogenesis. We sought to compare MRI T2 lesion evolution in myelin oligodendrocyte glycoprotein immunoglobulin G (IgG)-associated disorder (MOGAD), aquaporin 4 IgG-positive neuromyelitis optica spectrum disorder (AQP4-IgG-NMOSD), and multiple sclerosis (MS).In this descriptive study, we retrospectively identified Mayo Clinic patients with MOGAD, AQP4-IgG-NMOSD, or MS and (1) brain or myelitis attack; (2) available attack MRI within 6 weeks; and (3) follow-up MRI beyond 6 months without interval relapses in that region. Two neurologists identified the symptomatic or largest T2 lesion for each patient (index lesion). MRIs were then independently reviewed by 2 neuroradiologists blinded to diagnosis to determine resolution of T2 lesions by consensus. The index T2 lesion area was manually outlined acutely and at follow-up to assess variation in size.METHODSIn this descriptive study, we retrospectively identified Mayo Clinic patients with MOGAD, AQP4-IgG-NMOSD, or MS and (1) brain or myelitis attack; (2) available attack MRI within 6 weeks; and (3) follow-up MRI beyond 6 months without interval relapses in that region. Two neurologists identified the symptomatic or largest T2 lesion for each patient (index lesion). MRIs were then independently reviewed by 2 neuroradiologists blinded to diagnosis to determine resolution of T2 lesions by consensus. The index T2 lesion area was manually outlined acutely and at follow-up to assess variation in size.We included 156 patients (MOGAD, 38; AQP4-IgG-NMOSD, 51; MS, 67) with 172 attacks (brain, 81; myelitis, 91). The age (median [range]) differed between MOGAD (25 [2-74]), AQP4-IgG-NMOSD (53 [10-78]), and MS (37 [16-61]) (p < 0.01) and female sex predominated in the AQP4-IgG-NMOSD (41/51 [80%]) and MS (51/67 [76%]) groups but not among those with MOGAD (17/38 [45%]). Complete resolution of the index T2 lesion was more frequent in MOGAD (brain, 13/18 [72%]; spine, 22/28 [79%]) than AQP4-IgG-NMOSD (brain, 3/21 [14%]; spine, 0/34 [0%]) and MS (brain, 7/42 [17%]; spine, 0/29 [0%]) (p < 0.001). Resolution of all T2 lesions occurred most often in MOGAD (brain, 7/18 [39%]; spine, 22/28 [79%]) than AQP4-IgG-NMOSD (brain, 2/21 [10%]; spine, 0/34 [0%]) and MS (brain, 2/42 [5%]; spine, 0/29 [0%]) (p < 0.01). There was a larger median (range) reduction in T2 lesion area in mm2 on follow-up axial brain MRI with MOGAD (213 [55-873]) than AQP4-IgG-NMOSD (104 [0.7-597]) (p = 0.02) and MS (36 [0-506]) (p < 0.001) and the reductions in size on sagittal spine MRI follow-up in MOGAD (262 [0-888]) and AQP4-IgG-NMOSD (309 [0-1885]) were similar (p = 0.4) and greater than in MS (23 [0-152]) (p < 0.001).RESULTSWe included 156 patients (MOGAD, 38; AQP4-IgG-NMOSD, 51; MS, 67) with 172 attacks (brain, 81; myelitis, 91). The age (median [range]) differed between MOGAD (25 [2-74]), AQP4-IgG-NMOSD (53 [10-78]), and MS (37 [16-61]) (p < 0.01) and female sex predominated in the AQP4-IgG-NMOSD (41/51 [80%]) and MS (51/67 [76%]) groups but not among those with MOGAD (17/38 [45%]). Complete resolution of the index T2 lesion was more frequent in MOGAD (brain, 13/18 [72%]; spine, 22/28 [79%]) than AQP4-IgG-NMOSD (brain, 3/21 [14%]; spine, 0/34 [0%]) and MS (brain, 7/42 [17%]; spine, 0/29 [0%]) (p < 0.001). Resolution of all T2 lesions occurred most often in MOGAD (brain, 7/18 [39%]; spine, 22/28 [79%]) than AQP4-IgG-NMOSD (brain, 2/21 [10%]; spine, 0/34 [0%]) and MS (brain, 2/42 [5%]; spine, 0/29 [0%]) (p < 0.01). There was a larger median (range) reduction in T2 lesion area in mm2 on follow-up axial brain MRI with MOGAD (213 [55-873]) than AQP4-IgG-NMOSD (104 [0.7-597]) (p = 0.02) and MS (36 [0-506]) (p < 0.001) and the reductions in size on sagittal spine MRI follow-up in MOGAD (262 [0-888]) and AQP4-IgG-NMOSD (309 [0-1885]) were similar (p = 0.4) and greater than in MS (23 [0-152]) (p < 0.001).The MRI T2 lesions in MOGAD resolve completely more often than in AQP4-IgG-NMOSD and MS. This has implications for diagnosis, monitoring disease activity, and clinical trial design, while also providing insight into pathogenesis of CNS demyelinating diseases.DISCUSSIONThe MRI T2 lesions in MOGAD resolve completely more often than in AQP4-IgG-NMOSD and MS. This has implications for diagnosis, monitoring disease activity, and clinical trial design, while also providing insight into pathogenesis of CNS demyelinating diseases.
Author Chen, John J
Weinshenker, Brian G
Monaco, Salvatore
Nguyen, Adam
Zalewski, Nicholas L
Kunchok, Amy
Flanagan, Eoin P
Fryer, James P
Lopez-Chiriboga, A Sebastian
Keegan, B Mark
Messina, Steven A
Pittock, Sean J
Lucchinetti, Claudia F
Syc-Mazurek, Stephanie B
Morris, Padraig P
Greenwood, Tammy
Sechi, Elia
Buciuc, Marina
Krecke, Karl N
Tillema, Jan Mendelt
Author_xml – sequence: 1
  givenname: Elia
  orcidid: 0000-0003-4698-663X
  surname: Sechi
  fullname: Sechi, Elia
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 2
  givenname: Karl N
  surname: Krecke
  fullname: Krecke, Karl N
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 3
  givenname: Steven A
  surname: Messina
  fullname: Messina, Steven A
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 4
  givenname: Marina
  orcidid: 0000-0003-4826-5430
  surname: Buciuc
  fullname: Buciuc, Marina
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 5
  givenname: Sean J
  surname: Pittock
  fullname: Pittock, Sean J
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 6
  givenname: John J
  surname: Chen
  fullname: Chen, John J
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 7
  givenname: Brian G
  orcidid: 0000-0001-5806-6203
  surname: Weinshenker
  fullname: Weinshenker, Brian G
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 8
  givenname: A Sebastian
  surname: Lopez-Chiriboga
  fullname: Lopez-Chiriboga, A Sebastian
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 9
  givenname: Claudia F
  surname: Lucchinetti
  fullname: Lucchinetti, Claudia F
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 10
  givenname: Nicholas L
  surname: Zalewski
  fullname: Zalewski, Nicholas L
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 11
  givenname: Jan Mendelt
  surname: Tillema
  fullname: Tillema, Jan Mendelt
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 12
  givenname: Amy
  surname: Kunchok
  fullname: Kunchok, Amy
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 13
  givenname: Salvatore
  surname: Monaco
  fullname: Monaco, Salvatore
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 14
  givenname: Padraig P
  surname: Morris
  fullname: Morris, Padraig P
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 15
  givenname: James P
  surname: Fryer
  fullname: Fryer, James P
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 16
  givenname: Adam
  surname: Nguyen
  fullname: Nguyen, Adam
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 17
  givenname: Tammy
  surname: Greenwood
  fullname: Greenwood, Tammy
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 18
  givenname: Stephanie B
  surname: Syc-Mazurek
  fullname: Syc-Mazurek, Stephanie B
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 19
  givenname: B Mark
  orcidid: 0000-0002-2880-935X
  surname: Keegan
  fullname: Keegan, B Mark
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL
– sequence: 20
  givenname: Eoin P
  orcidid: 0000-0002-6661-2910
  surname: Flanagan
  fullname: Flanagan, Eoin P
  email: flanagan.eoin@mayo.edu
  organization: From the Departments of Neurology (E.S., M.B., S.J.P., J.J.C., B.G.W., C.F.L., N.L.Z., J.M.T., A.K., S.B.S.-M., B.M.K., E.P.F.), Radiology (K.N.K., S.A.M., P.P.M.), Laboratory Medicine and Pathology (S.J.P., J.P.F., A.N., E.P.F.), and Ophthalmology (J.J.C., T.G.), Mayo Clinic, Rochester, MN; Department of Neurosciences, Biomedicine, and Movement Sciences (E.S., S.M.), University of Verona, Italy; and Department of Neurology (A.S.L.-C.), Mayo Clinic, Jacksonville, FL. flanagan.eoin@mayo.edu
BackLink https://www.ncbi.nlm.nih.gov/pubmed/34261784$$D View this record in MEDLINE/PubMed
BookMark eNpNkN1LwzAUxYNM3If-ByJ59KWzSZumfZRu00Gd4Af6ZEmbW4m0yUzawf57I070Ptx7Dvy4HM4UjbTRgNA5CeeEEnr1sinm4d8QGif8CE0Io0mQRPR19E-P0dS5Dw8xyrMTNI5imhCexhP0lptuK6xyRmPT4LuHNS7AKe-WO9MO_bdSGi9U04AF3ePcLytavAG7M4PDj3vXQ4cX0O2hVVr0Sr973BkrwbpTdNyI1sHZ4c7Q82r5lN8Gxf3NOr8ugpqRjAeNj0OFkHEliRQiYzyEOolkWnsrvYSGVRCzVPAqZE1EgQueMAlhxeokI3SGLn_-bq35HMD1ZadcDW0rNPiUJWWcsihMaerRiwM6VB3IcmtVJ-y-_O2EfgFn_2e_
CitedBy_id crossref_primary_10_1016_j_msard_2022_104057
crossref_primary_10_1016_j_jns_2021_120044
crossref_primary_10_1093_brain_awac480
crossref_primary_10_1212_NXI_0000000000200309
crossref_primary_10_3348_kjr_2023_0360
crossref_primary_10_1016_j_autrev_2024_103693
crossref_primary_10_1080_14728214_2025_2565189
crossref_primary_10_1177_13524585251367343
crossref_primary_10_1136_jnnp_2023_331137
crossref_primary_10_1016_j_msard_2023_104613
crossref_primary_10_1212_WNL_0000000000209321
crossref_primary_10_1177_13524585241307154
crossref_primary_10_1007_s00415_023_11737_8
crossref_primary_10_1016_j_ncl_2023_06_009
crossref_primary_10_1007_s13311_022_01206_x
crossref_primary_10_17116_jnevro202312311147
crossref_primary_10_1093_braincomms_fcaf280
crossref_primary_10_1212_WNL_0000000000214075
crossref_primary_10_3389_fneur_2023_1210972
crossref_primary_10_1111_jon_13137
crossref_primary_10_1016_S1474_4422_22_00431_8
crossref_primary_10_1177_13524585221150743
crossref_primary_10_3390_ijms232314559
crossref_primary_10_1016_j_jneuroim_2022_577812
crossref_primary_10_1002_ana_26502
crossref_primary_10_1002_glia_70044
crossref_primary_10_3389_fimmu_2025_1530977
crossref_primary_10_1016_j_jns_2022_120269
crossref_primary_10_1016_j_jns_2025_123413
crossref_primary_10_1016_j_msard_2021_103424
crossref_primary_10_1097_MCC_0000000000001139
crossref_primary_10_1007_s00415_023_11634_0
crossref_primary_10_1016_j_msard_2022_104436
crossref_primary_10_37549_AR_D_24_0020
crossref_primary_10_3389_fimmu_2023_1237149
crossref_primary_10_1016_j_clineuro_2025_109111
crossref_primary_10_1016_j_actbio_2023_08_033
crossref_primary_10_1055_a_2297_0591
crossref_primary_10_1016_j_mric_2025_01_004
crossref_primary_10_1177_13524585231188485
crossref_primary_10_1212_NXI_0000000000200329
crossref_primary_10_1212_WNL_0000000000209303
crossref_primary_10_1212_WNL_0000000000201263
crossref_primary_10_1016_j_msard_2024_105559
crossref_primary_10_1002_ana_27309
crossref_primary_10_1038_s41582_024_01005_2
crossref_primary_10_1136_jnnp_2023_333227
crossref_primary_10_1177_19714009251356989
crossref_primary_10_3389_fimmu_2022_870867
crossref_primary_10_7759_cureus_43775
crossref_primary_10_1097_WCO_0000000000001362
crossref_primary_10_3389_fneur_2022_993645
crossref_primary_10_3389_fnhum_2021_782490
crossref_primary_10_1016_S1474_4422_23_00148_5
crossref_primary_10_1212_NXI_0000000000200456
crossref_primary_10_1016_j_msard_2022_103727
crossref_primary_10_1016_j_msard_2023_104659
crossref_primary_10_1111_ene_15178
crossref_primary_10_3389_fimmu_2025_1535571
crossref_primary_10_1136_jnnp_2023_332542
crossref_primary_10_1212_NXI_0000000000200344
crossref_primary_10_1177_20552173211048761
crossref_primary_10_3389_fneur_2021_679881
crossref_primary_10_1136_bcr_2022_248921
crossref_primary_10_1016_j_msard_2025_106394
crossref_primary_10_1080_14737175_2023_2195095
crossref_primary_10_1111_epi_17315
crossref_primary_10_1016_j_msard_2023_104787
crossref_primary_10_3389_fneur_2022_1011579
crossref_primary_10_1055_a_1671_1066
crossref_primary_10_1016_j_jneuroim_2021_577750
crossref_primary_10_1212_WNL_0000000000207637
crossref_primary_10_1001_jamanetworkopen_2021_37833
crossref_primary_10_1111_ene_15983
crossref_primary_10_1007_s00415_024_12585_w
crossref_primary_10_1097_WNO_0000000000001772
crossref_primary_10_1212_WNL_0000000000207238
crossref_primary_10_1212_WNL_0000000000213903
crossref_primary_10_1212_WNL_0000000000206820
crossref_primary_10_1016_j_neurad_2024_101235
crossref_primary_10_1212_WNL_0000000000201465
crossref_primary_10_1002_ana_26549
crossref_primary_10_1016_j_msard_2024_105926
crossref_primary_10_1007_s00247_024_06023_2
crossref_primary_10_1212_CON_0000000000001454
crossref_primary_10_1212_NXI_0000000000200400
crossref_primary_10_1002_ana_26279
crossref_primary_10_1177_13524585251359450
crossref_primary_10_1002_ana_26951
crossref_primary_10_1002_brb3_70310
crossref_primary_10_1016_j_autrev_2023_103465
crossref_primary_10_1016_j_ijbiomac_2024_131964
crossref_primary_10_1177_13524585221097564
crossref_primary_10_1016_j_msard_2024_105596
crossref_primary_10_1055_a_2114_1350
crossref_primary_10_1186_s12883_022_02837_5
crossref_primary_10_1053_j_ro_2024_03_007
crossref_primary_10_1177_13524585231166834
crossref_primary_10_4103_aian_aian_949_21
crossref_primary_10_1177_13524585231221664
crossref_primary_10_3389_fneur_2022_885218
crossref_primary_10_1093_cei_uxad075
crossref_primary_10_1177_13524585231187120
crossref_primary_10_1212_CON_0000000000001464
crossref_primary_10_1007_s11910_024_01344_z
crossref_primary_10_1016_j_bnd_2024_10_001
crossref_primary_10_1016_j_msard_2025_106460
crossref_primary_10_1017_cjn_2022_324
ContentType Journal Article
Copyright Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
Copyright_xml – notice: Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
DBID CGR
CUY
CVF
ECM
EIF
NPM
7X8
DOI 10.1212/WNL.0000000000012467
DatabaseName Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
MEDLINE - Academic
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Medicine
EISSN 1526-632X
ExternalDocumentID 34261784
Genre Research Support, Non-U.S. Gov't
Journal Article
Research Support, N.I.H., Extramural
GrantInformation_xml – fundername: NINDS NIH HHS
  grantid: R01 NS113828
GroupedDBID ---
-~X
.XZ
.Z2
01R
0R~
123
1J1
29N
354
3PY
4Q1
4Q2
4Q3
53G
5RE
5VS
6PF
77Y
AAAXR
AAGIX
AAHPQ
AAIQE
AAJCS
AAMOA
AAMTA
AAQKA
AARTV
AASCR
AASOK
AASXQ
AAWTL
AAXQO
AAYEP
ABBLC
ABIVO
ABJNI
ABOCM
ABVCZ
ABXYN
ABZZY
ACDDN
ACGFS
ACIJW
ACILI
ACLDA
ACOAL
ACWRI
ACXJB
ACZKN
ADGGA
AE6
AEBDS
AENEX
AFDTB
AFEXH
AFNMH
AFUWQ
AGINI
AHOMT
AHQNM
AHQVU
AHVBC
AIJEX
AJCLO
AKCTQ
AKULP
AKWKN
ALMA_UNASSIGNED_HOLDINGS
AMJPA
AMKUR
AMNEI
AOHHW
BOYCO
BQLVK
BYPQX
C45
CGR
CS3
CUY
CVF
DIWNM
DU5
E.X
EBS
ECM
EIF
EJD
ERAAH
EX3
F2K
F2L
F2M
F2N
F5P
FCALG
GQDEL
HZ~
IKYAY
IN~
IPNFZ
JF7
KD2
KMI
L-C
L7B
N9A
NPM
N~7
N~B
O9-
OAG
OAH
OBH
ODMTH
OHH
OHYEH
OL1
OLB
OLH
OLU
OLV
OLY
OLZ
OPX
OVD
OVDNE
OVIDH
OVLEI
OWU
OWV
OWW
OWX
OWY
OWZ
OXXIT
P2P
RIG
RLZ
RXW
SJN
TEORI
V2I
VVN
W3M
WH7
WOQ
WOW
XSW
XXN
XYM
XYN
YBU
YCJ
YFH
~9M
7X8
ABPXF
ADKSD
ADSXY
ID FETCH-LOGICAL-c5197-f2612aad4bd1daa9570ec63d8c1dadec6ef5be458a7b05f32e7a765de0b5c6912
IEDL.DBID 7X8
ISICitedReferencesCount 113
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=00006114-202109140-00007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1526-632X
IngestDate Mon Sep 08 18:04:05 EDT 2025
Thu Apr 03 07:05:06 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 11
Language English
License Copyright © 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5197-f2612aad4bd1daa9570ec63d8c1dadec6ef5be458a7b05f32e7a765de0b5c6912
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0002-6661-2910
0000-0003-4826-5430
0000-0001-5806-6203
0000-0003-4698-663X
0000-0002-2880-935X
OpenAccessLink https://n.neurology.org/content/neurology/97/11/e1097.full.pdf
PMID 34261784
PQID 2572530828
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2572530828
pubmed_primary_34261784
PublicationCentury 2000
PublicationDate 2021-09-14
20210914
PublicationDateYYYYMMDD 2021-09-14
PublicationDate_xml – month: 09
  year: 2021
  text: 2021-09-14
  day: 14
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
PublicationTitle Neurology
PublicationTitleAlternate Neurology
PublicationYear 2021
SSID ssj0015279
Score 2.647971
Snippet There are few studies comparing lesion evolution across different CNS demyelinating diseases, yet knowledge of this may be important for diagnosis and...
SourceID proquest
pubmed
SourceType Aggregation Database
Index Database
StartPage e1097
SubjectTerms Adolescent
Adult
Aged
Brain - diagnostic imaging
Brain - pathology
Child
Child, Preschool
Demyelinating Diseases - diagnostic imaging
Demyelinating Diseases - pathology
Disease Progression
Female
Humans
Magnetic Resonance Imaging
Male
Middle Aged
Multiple Sclerosis - diagnostic imaging
Multiple Sclerosis - pathology
Retrospective Studies
Young Adult
Title Comparison of MRI Lesion Evolution in Different Central Nervous System Demyelinating Disorders
URI https://www.ncbi.nlm.nih.gov/pubmed/34261784
https://www.proquest.com/docview/2572530828
Volume 97
WOSCitedRecordID wos00006114-202109140-00007&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1JS8QwFA7qiHhxX8aNCF7LdNqmSU4is6AwUwZR7MmSrTAH29GOA_57X9qMc_Eg2MNreyiE8PXlLcn3IXQjecyV7EovyCUkKIYLD1Dig9FhyIkWjMlabIImCUtTPnEFt8ptq1z6xNpR61LZGnkHoBUQy63CbmfvnlWNst1VJ6GxjlohhDIW1TRddRFIUHPtwT324jBI3dE58Nadl2TUUBc2F6xyjdL870FmvdgMd_87zD2048JMfNfgYh-tmeIAbY1dI_0QvfZ-9AdxmePx4wMeGVs4w4OFAyOeFrjv5FPm2FWBcQK-pfyscMN0jvvm7cueaBd29zReUnlWR-h5OHjq3XtOasFT9uSql1smMSF0JHVXC8EJ9Y2KQ80UvGp4NDmRJiJMUOmTPAwMFTQm2viSqJh3g2O0UZSFOUVYGOULGWkmwXKId7TmjAZhrGQEuRJto-vlzGUAZdufEIWBkWeruWujk2b6s1nDuZGFNtWjLDr7w9fnaDuwO0-s0EN0gVo5_MjmEm2qxXxafVzVGAGbTMbfHQ_HAw
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Comparison+of+MRI+Lesion+Evolution+in+Different+Central+Nervous+System+Demyelinating+Disorders&rft.jtitle=Neurology&rft.au=Sechi%2C+Elia&rft.au=Krecke%2C+Karl+N&rft.au=Messina%2C+Steven+A&rft.au=Buciuc%2C+Marina&rft.date=2021-09-14&rft.issn=1526-632X&rft.eissn=1526-632X&rft.volume=97&rft.issue=11&rft.spage=e1097&rft_id=info:doi/10.1212%2FWNL.0000000000012467&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1526-632X&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1526-632X&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1526-632X&client=summon